Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in Intermediate Trophoblastic Tumors
NCT06941766Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete Response Rate up to 1 year. Started Apr 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
placental site trophoblastic tumor (PSTT)epithelioid trophoblastic tumor (ETT)
Beyond the preview
Go deeper on NCT06941766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941766.